Investing.com
Published Apr 06, 2022 18:26
InterCure Ltd. (TASE:INCR) is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2021. References herein to preliminary results refer to the preliminary results published by the Company on February 8, 2022. All amounts are expressed in New Israeli Shekels (NIS) or Canadian dollars ($), unless otherwise noted.
Fourth Quarter 2021 Key Financial & Operating Highlights
Full Year 2021 Key Financial & Operating Highlights
Post-Fourth Quarter 2021 Highlights
"Our fourth quarter results came in stronger than we initially expected as we successfully continue to expand InterCure's branded product portfolio, scale up our unique global supply chain and expand our pharmaceutical grade medical cannabis dispensing operation," said InterCure CEO Alexander Rabinovitch, adding "Our results throughout 2021 reflect the outstanding work we've accomplished and our focus on executing our profitable growth strategy. As regulations are evolving favorably, there is huge potential in all of our operating territories, and we are well positioned for the growth ahead. We will continue focusing on executing our profitable growth strategy, creating value for our stakeholders."
Key Q4 and Full Year 2021 Financial Highlights "Cannabis Sector"
(In thousands $)
Full Year | 2020 | 2021(Preliminary) | 2021 |
Revenues | 26,628 | 87,000 | 88,779 |
Gross Profit(1) | 12,441 | 37,799 | |
Adjusted EBITDA(2) | 6,508 | 22,566 |
Fourth Quarter | Q4-20 | Q4-21(Preliminary) | 2021 |
Revenues | 11,093 | 31,000 | 32,632 |
Gross Profit(1) | 5,446 | 14,990 | |
Adjusted EBITDA(2) | 3,549 | 8,635 |
Q2-20 | Q3-20 | Q4-20 | Q1-21 | Q2-21 | Q3-21 | Q4-21 | ||||||||
Revenues | 4,580 | 9,211 | 11,093 | 13,532 | 18,518 | 25,260 | 32,632 | |||||||
Gross Profit(1) | 1,971 | 4,403 | 5,446 | 6,316 | 7,889 | 10,106 | 14,990 | |||||||
GP Margin | 43% | 48% | 49% | 47% | 43% | 40% | 46% | |||||||
Adjusted EBITDA(2) | 644 | 2,852 | 3,549 | 4,121 | 4,791 | 5,749 | 8,635 | |||||||
Adjusted EBITDA(2) Margin | 14% | 31% | 32% | 30% | 26% | 23% | 26% |
(1) Gross profit before effect of fair value.(2) EBITDA adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, non-controlling interest, and other expenses (or income). This is a non-IFRS financial measure and does not have a standardized meaning prescribed by IFRS, please see Non-IFRS Measures below.
Rescheduled Webcast and Conference Call
Management will conduct a webcast on Wednesday, April 6, 2022 at 5:30 p.m. (Eastern Time) to review the results as well as provide an overview of the Companys's recent milestones and growth strategy.
To access the conference call, United States participants please dial (844) 310-5056, or for international callers, 1-706-679-4749. Conference ID: 5661207.
Participants can access the live webcast through the following link:https://bit.ly/37N92wN
Consolidated Financial Statements and Management's Discussion and Analysis
The publication of InterCure's audited financial statements and accompanying notes for the year ended December 31, 2021 and related management's discussion and analysis of financial condition and results of operations ("MD&A") are available under the Company's profile on SEDAR.
About InterCure (dba Canndoc)
InterCure (dba Canndoc) (INCR) (INCR.U) (INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israels largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its international market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.
For more information, visit: http://www.intercure.co.
Non-IFRS Measures
This press release makes reference to certain non-IFRS financial measures. Adjusted EBITDA, as defined by InterCure, means earnings before interest, income taxes, depreciation, and amortization, adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, non-controlling interest and other expenses (or income). This measure is not a recognized measure under IFRS, does not have a standardized meaning prescribed by IFRS and is therefore unlikely to be comparable to similar measures presented by other companies. InterCure's method of calculating this measure may differ from methods used by other entities and accordingly, this measure may not be comparable to similarly titled measured used by other entities or in other jurisdictions. InterCure uses this measure because it believes it provides useful information to both management and investors with respect to the operating and financial performance of the company. A reconciliation of Adjusted EBITDA to an IFRS measure (revenue) is provided below:
Adjusted EBITDA Reconciliation (consolidated base) | FOURTH QUARTER | FULL YEAR | |||||
Q4-20 | Q4-21 | 2020 | 2021 | ||||
Comprehensive income (loss) | 4,188 | (1,244) | (14,756) | 2,987 | |||
Interest / Financing cost | (94) | 2,659 | (38) | 3,870 | |||
Tax expenses (income) | (1,042) | 2,291 | (929) | 4,684 | |||
Depreciation and amortization | 438 | 1,314 | 1,332 | 3,027 | |||
EBITDA | 3,491 | 5,020 | (14,391) | 14,568 | |||
Share-based payment expenses | 686 | 479 | 4,098 | 2,641 | |||
Other expenses (income), net | 381 | 643 | 1,868 | 1,217 | |||
Impairment losses and (gains) on financial assets through profit and loss | (1,085) | 901 | 15,229 | 765 | |||
Fair value adjustment to inventory | (129) | 920 | (650) | 1,989 | |||
Adjusted EBITDA | 3,344 | 7,963 | 6,154 | 21,179 |
*All amounts shown in CAD
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.